Table 1.
Categories | SLE (n = 44) |
---|---|
Females, n (%) | 40 (89.0) |
Age, mean (S.D.), years | 39.0 ± 15.0 |
SLEDAI score, mean (S.D.) | 9.2 ± 6.1 |
ds-DNA (+, > 100 IU/mL), n (%) (43 patients) | 21 (48.8) |
Anti-ENA (42 patients) | |
Anti-Sm, n (%) | 11 (26.2) |
Anti-Ro52, n (%) | 21 (50.0) |
Anti-nRNP/Sm, n (%) | 15 (35.7) |
Anti-rRNP, n (%) | 13 (31.0) |
Anti-nucleosome, n (%) | 17 (40.5) |
Anti-SSA, n (%) | 29 (69.0) |
Anti-SSB, n (%) | 2 (4.8) |
Decreased C3, n (%) | 31 (70.5) |
Decreased C4, n (%) | 29 (65.9) |
Increased IgG, n (%) | 21 (47.7) |
Elevated ESR, n (%) | 27 (61.4) |
Clinical features | |
Fever, n (%) | 4 (9.1) |
Cutaneous manifestations, n (%) | 20 (45.5) |
Oral ulcer, n (%) | 3 (6.8) |
Alopecia, n (%) | 8 (18.2) |
Arthritis, n (%) | 16 (36.4) |
Neuropathic lupus, n (%) | 3 (6.8) |
Effusion, n (%) | 8 (18.2) |
24 hours proteinuria, n (%) | 10 (22.7) |
Hematuresis, n (%) | 6 (13.6) |
Pyuria, n (%) | 5 (11.4) |
Leucopenia | 13 (29.5) |
Erythrocytopenia | 21 (47.7) |
Thrombocytopenia | 9 (20.5) |
Anemia | 23 (52.3) |
Anti-dsDNA, anti double-stranded DNA; Anti-ENA, anti extractable nuclear antigen; C3, complement 3; C4, complement 4; ESR, erythrocyte sedimentation rate; IgG, immunoglobulin G; RNP, ribonucleoprotein; rRNP, ribosomal RNP; SLE, Systemic lupus erythematosus; SLEDAI, SLE disease activity index; WBC, white blood cell.